Shorter length dialysis sessions are associated with increased mortality, independent of body weight  by Flythe, Jennifer E. et al.
Shorter length dialysis sessions are associated with
increased mortality, independent of body weight
Jennifer E. Flythe1,2, Gary C. Curhan1,2,3 and Steven M. Brunelli1,2,4
1Division of Nephrology, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Harvard Medical
School, Boston, Massachusetts, USA; 3Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Boston,
Massachusetts, USA and 4Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital, Boston,
Massachusetts, USA
Hemodialysis patients have high rates of mortality that may
be related to aspects of the dialytic procedure. In prior
studies, shorter length dialysis sessions have been associated
with decreased survival, but these studies may have been
confounded by body size differences. Here we tested
whether in-center three-times-weekly hemodialysis patients
with adequate urea clearances but shorter dialysis session
length is associated with mortality independent of body size.
Data were taken from a large national cohort of patients from
a large dialysis organization undergoing three-times-weekly
in-center hemodialysis. In the primary analysis, patients with
prescribed dialysis sessions greater and less than 240min
were pair-matched on post-dialysis weight as well as on age,
gender, and vascular access type. Compared to prescribed
longer dialysis sessions, session lengths less than 240min
were significantly associated with increased all-cause
mortality (adjusted hazard ratio 1.26). The association was
consistent across strata of age, gender, and dialysis
post-weight. Secondary analyses found a dose–response
between prescribed session length and survival. Thus, among
patients with adequate urea clearance, shorter dialysis
session lengths are associated with increased mortality
independent of body weight.
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The United States is home to over 380,000 chronic
hemodialysis (HD) patients, a population expected to surpass
500,000 by 2020.1 The vast majority of these patients undergo
three-times-weekly in-center dialysis. Mortality rates among
US HD patients have remained unacceptably high over the
past several decades, despite advances in dialysate purity,
membrane technology, and patient monitoring.1 US HD
patients fair worse than their counterparts in Europe, Japan,
and Australia/New Zealand even when case-mix differences
are accounted for,2 suggesting that differences in dialysis
processes may have significant bearing on mortality.
Prior observational studies have demonstrated that
shorter dialysis session length (DSL) is associated with
increased mortality.3–7 This association may be mediated
through consequent need for more rapid ultrafiltration3,8,9
or through limitations in solute clearance not reflected by
standard clinical biochemical markers. However, the absence
of supporting evidence from randomized controlled trials
renders such observational findings subject to circumspec-
tion. Detractors have rightfully noted that body size is an
important determinant of DSL and is also (presumably
independently) associated with mortality, suggesting that
past studies have been residually confounded by body size
discrepancies.10,11 Specifically, smaller body size is associated
with greater mortality, and smaller patients are typically
dialyzed for shorter times; ergo, the resultant bias would
favor longer DSL.12–14
It is critical to further clarify whether the association
between DSL and mortality is potentially causal. If so, the
extension of DSL would provide a readily modifiable means
by which to improve patient longevity. If not, the extension
of DSL may unnecessarily contribute to patient burden and
dissatisfaction.
Therefore, we undertook this study to clarify whether—in
the setting of three-times-weekly in-center HD and the
absence of compelling indication to extend DSL on the
basis of clearance (i.e., urea reduction ratio (URR)o65%)—
longer DSL is associated with reduced mortality inde-
pendent of body size differences. We used data from a
large, contemporary, prevalent cohort from a large dialysis
organization (LDO) that is similar to the broader US HD
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population in terms of patient characteristics and dialytic
practice patterns. To tightly control for confounding on the
basis of body size as well as other key covariates, patients were
matched according to post-dialysis weight, gender, age, and
vascular access type.
RESULTS
Baseline characteristics of cohort
Demographic, clinical, and biochemical characteristics of the
source population are shown in Table 1. The source cohort
(of eligible participants) consisted of 10,571 subjects with a
mean age of 62.2±15.0 years; 48.3% were women and 39.5%
were Black. At baseline, 37.8% had a history of congestive
heart failure and 52.5% were diabetic; mean URR was 74.5%;
patients were dialyzed via a fistula (37.3%), graft (31.9%),
and catheter (30.0%). The mean prescribed DSL (RxDSL)
was 217±26min; 6791 (64.2%) and 3780 (35.8%) patients
had RxDSL o240 and X240min, respectively. The mean
dialytic vintage of this prevalent cohort was 2.5 years at the
start of the study. Overall, the RxDSL o240 and RxDSL
X240 groups were similar in terms of dialytic vintage,
predialysis systolic blood pressure, and the number of missed
sessions during the 30-day exposure period. Before matching,
RxDSL o240 subjects were more likely to be lighter, older,
and female; subjects with RxDSL X240 were more likely to
be Black and to have diabetes, congestive heart failure, and
coronary artery disease.
Primary analysis
In the primary analysis, 2382 subjects with RxDSL X240
(63% of the source population) were successfully matched
to one individual with RxDSL o240. The matched pairs
demonstrated excellent balance on all matching factors
including weight (Table 2; Supplementary Figure SA online).
The mean age was 61.6±13.0 and 61.7±13.0 years in the
RxDSL X240 vs. RxDSL o240 groups. In both groups, the
mean post-dialysis weight was 76.7±14.9 kg.
Overall, 1477 deaths occurred during 9676 patient-years of
at-risk time. Median at-risk time was 24.4 months after the
start of the study. Compared with RxDSL X240, RxDSL
o240 was associated with an unadjusted hazard ratio (HR)
(95% confidence interval (CI)) of 1.11 (0.97–1.26; P¼ 0.12).
When residual imbalances between RxDSL groups were
accounted for, a potent and statistically significant associa-
tion between RxDSL o240 and mortality was observed:
adjusted HR (95% CI) 1.26 (1.07–1.48; P¼ 0.005) (Figure 1).
Results were slightly attenuated when URR was considered as
a variable in the multivariable model (adjusted HR (95% CI)
1.23 (1.04–1.45)), but URR was excluded from the final
model on the presumption that it functions as an
intermediate on one causal pathway linking RxDSL to
mortality. Restriction subgroup analyses demonstrated stable
estimates across strata of age (P-interaction¼ 0.61), gender
(P-interaction¼ 0.79), race (P-interaction¼ 0.76), and post-
dialysis weight (P-interaction¼ 0.76) (Figure 2).
To explore for dose–response in the RxDSL—mortality
association, we calculated the difference in RxDSL between
members of each matched pair. Pairs were then categorized as
having an RxDSL difference ofo30, ¼ 30, or430min, and
the association between RxDSLo240 and RxDSLX240 was
estimated within each stratum. As demonstrated in Table 3,
the magnitude of the association between RxDSL o240
(compared with RxDSLX240) and mortality was incremen-
tally more potent when differences in RxDSL were greater,
suggestive of a dose–response trend.
Secondary analyses
To further examine the association between RxDSL and
mortality, we categorized subjects as having RxDSL o210,
RxDSL210–239, and RxDSL X240. In this analysis, 691
RxDSL X240 subjects were successfully matched to both
one RxDSL 210–239 subject and one RxDSL o210 subject.
The matched triplets demonstrated excellent balance on all
matching factors (Table 4). Overall, 686 deaths occurred
during 4141 patient-years of at-risk time. Median at-risk time
was 22.8 months after the start of the study. Compared with
RxDSL X240, shorter RxDSL was incrementally associated
with greater mortality (adjusted HRs (95% CIs) 1.28
(0.98–1.67) for RxDSL 210–239 and 1.30 (1.02–1.68) for
RxDSL o210; P-trend¼ 0.038) (Figure 1).
DISCUSSION
Prior analyses of the DSL–mortality association may have
failed to adequately account for potential confounding on the
basis of body size differences and, as a result, the validity of
their conclusions has been questioned. In this analysis, we
demonstrate that shorter RxDSL is associated with increased
mortality even when body weight differences are strictly
controlled through matching. In addition, the data suggest a
dose–response relationship between DSL and survival. These
findings add credence to the notion that longer DSL—
beyond what is necessary to achieve contemporary urea
clearance targets—may promote greater survival. Subgroup
analyses suggest that the observed associations are similar
across strata of age, gender, and post-dialysis weight.
Prior observational studies examining the DSL–mortality
relationship have shown an association between shorter DSL
and mortality. In an Australian and New Zealand cohort,
Marshall et al.5 demonstrated that DSLo3.5 h was associated
with increased mortality (HR 1.57; 95% CI 1.14–2.17)
compared with 4–4.4 h of dialysis. In a subsequent study
using data from the Dialysis Outcomes and Practice Patterns
Study, Saran et al.3 showed that DSL of 211–240min was
associated with worse survival (HR 1.19; P¼ 0.01) compared
with DSL4240min. In a more recent study of incident HD
patients, Brunelli et al.6 demonstrated an HR of 1.42 (95% CI
1.24–1.62) for RxDSL o240min compared with sessions
X240min; because that study considered an incident dialysis
cohort and session length was frequently titrated during
follow-up, marginal structural analysis was used to account
for session length titrations made throughout the period of
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Table 1 | Baseline characteristics of overall source population across binary RxDSLa
Total (N¼ 10,571) RxDSLo240 (n¼ 6791) RxDSL X240 (n¼ 3780) P-value
RxDSL (min) —
Mean±s.d. 216.5±26.1 200.8±17.8 244.6±9.6
Median (IQR) 210 (195, 240) 210 (180, 210) 240 (240, 240)
Delivered DSL (min) 215.8±25.6 201.2±18.1 242.0±13.2 o0.001
Age (years) 62.2±15.0 64.2±15.2 58.6±13.8 o0.001
Female 5107 (48.3%) 3864 (56.9%) 1243 (32.9%) o0.001
Access o0.001
Fistula 3946 (37.3%) 2402 (35.4%) 1544 (40.9%)
Graft 3369 (31.9%) 2298 (33.8%) 1071 (28.3%)
Catheter 3166 (30.0%) 2027 (29.9%) 1139 (30.1%)
Missing 90 (0.9%) 64 (0.9%) 26 (0.7%)
Post-dialysis weight (kg) 75.0±19.5 69.5±16.3 84.9±20.8 o0.001
Interdialytic weight gain (kg) 2.6±1.1 2.4±1.0 3.1±1.2 o0.001
Ultrafiltration rate (ml/h/kg) 10.1±4.2 10.6±4.5 9.2±3.5 o0.001
Race o0.001
Non-Black 6328 (59.9%) 4302 (63.4%) 2026 (53.6%)
Black 4176 (39.5%) 2446 (36.0%) 1730 (45.8%)
Missing 24 (0.6%) 43 (0.6%) 24 (0.6%)
Diabetes 5546 (52.5%) 3395 (50.0%) 2151 (56.9%) o0.001
Coronary artery disease 1308 (12.4%) 801 (11.8%) 507 (13.4%) 0.02
Congestive heart failure 3992 (37.8%) 2384 (35.1%) 1608 (42.5%) o0.001
Vintage (years) 0.41
o1 2598 (24.6%) 1705 (25.1%) 893 (23.6%)
1–2 1550 (14.7%) 1002 (14.8%) 548 (14.5%)
2–4 2651 (25.1%) 1697 (25.0%) 954 (25.2%)
X4 3734 (35.3%) 2364 (34.8%) 1370 (36.2%)
Missing 38 (0.4%) 23 (0.3%) 15 (0.4%)
Pre-dialysis SBP (mmHg) 0.14
p130 1525 (14.4%) 992 (14.6%) 533 (14.1%)
130–150 3441 (32.6%) 2200 (32.4%) 1241 (32.8%)
150–170 3657 (34.6%) 2386 (35.1%) 1271 (33.6%)
4170 1948 (18.4%) 1213 (17.9%) 735 (19.4%)
Urea reduction ratio (%) 74.5±5.2 74.7±5.2 74.3±5.2 o0.001
Missed sessionsb 0.54
0 7480 (70.8%) 4782 (70.4%) 2698 (71.4%)
1 1049 (9.9%) 670 (9.9%) 379 (10.0%)
2 916 (8.7%) 589 (8.7%) 327 (8.7%)
3 314 (3.0%) 210 (3.1%) 104 (2.8%)
X4 812 (7.7%) 540 (8.0%) 272 (7.2%)
Albumin (g/dl) 0.05
p3 705 (6.7%) 475 (7.0%) 230 (6.1%)
3–3.5 1890 (17.9%) 1229 (18.1%) 662 (17.5%)
3.5–4 4770 (45.1%) 3073 (45.3%) 1697 (45.0%)
44 3152 (29.8%) 1986 (29.2%) 1166 (30.9%)
Missing 54 (0.5%) 28 (0.4%) 26 (0.7%)
Creatinine o0.001
Quartile 1 2562 (24.2%) 1793 (26.4%) 770 (20.4%)
Quartile 2 2654 (25.1%) 1799 (26.5%) 854 (22.6%)
Quartile 3 2470 (23.4%) 1575 (23.2%) 895 (23.7%)
Quartile 4 2561 (24.2%) 1441 (21.2%) 1120 (29.6%)
Missing 324 (3.1%) 183 (2.7%) 141 (3.7%)
Phosphorus (mg/dl) o0.001
p4 2173 (20.6%) 1490 (21.9%) 684 (18.1%)
4–5 2764 (26.2%) 1827 (26.9%) 937 (24.8%)
Table 1 Continued on following page
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observation. These observational studies stand in contrast to
the HEMO Study, a randomized trial of dialysis dose that
demonstrated no benefit to enhanced dialysis intensity.15 The
HEMO Study, however, was not designed to study treatment
time independently of other factors. The HEMO investigators
note: ‘In the design of the HEMO Study, treatment time was
closely coupled with the patients’ randomized dose target,
volume of urea distribution, and achievable blood flow. As a
consequence, the HEMO Study did not provide a favorable
setting for evaluating the effect of treatment time
independently of these other factorsy.’16 In addition,
subjects were not randomized to differing treatment times,
DSL varied within study arms, and the delivered DSL
spanned a limited range (only 335 (18.2%) randomized
subjects had RxDSL X240min), hampering the study’s
ability to adequately evaluate the independent effect of
RxDSL o240 vs. RxDSL X240 on mortality. In the absence
of any contemporary randomized trial data, we are left to
cautiously interpret observational data with respect to
treatment time.
Each of the above observational studies was adjusted for
some measure of body size through inclusion of covariate
terms in multivariable models. However, multivariable
adjustment is imperfect and may engender residual con-
founding. The influence of such residual confounding is
proportionate to several factors including: (1) imbalance in
body size across RxDSL groups, (2) strength of the
association between body size and mortality, (3) misspeci-
fication of the body size–mortality association in the
statistical model, (4) interactions between body size and
other covariates, and (5) overinfluence of extreme outliers
(e.g., the fate of one or two 250 kg patients).
Some have (rightfully) questioned the validity of past
findings on this basis.10 On average, heavier patients undergo
dialysis for a longer period,3,17 and body size is a strong
predictor of survival.12–14 By tightly matching, we were able
to precisely balance post-dialysis weight across RxDSL groups
and greatly reduce the opportunity for confounding on this
basis. In addition, by matching on additional factors that
weigh heavily in DSL determination and are also key
mortality determinants (age, gender, and vascular access),
we minimized confounding on these bases. Because matching
obviates the need for assumptions regarding the pattern of
association between matching factors and outcome, errors
due to model misspecification are averted. Matching also
accounts for interaction between the matching factor and
other confounders (e.g., a serum creatinine of 12 has a
different implication in 130 kg male patients than in 50 kg
female patients). Such interactions are often not considered
in standard multivariable analyses. Finally, and perhaps most
importantly, matching implicitly excludes patients in whom
DSL is deterministic (e.g., patients at the extremes of body
weight for whom a suitable match cannot be identified) and
those who are not appropriate targets for inference because
the decision between o240 and X240 is immaterial. Such
‘trimming’ limited the range of post-dialysis weights to
41.5–153.3 kg in our matched cohort. This improves the
validity of inference within the population studied, although
at the expense of generalizability. Hence, this matched
analysis is better able to address confounding by body size
than were prior studies. As empiric demonstration, we
repeated the primary analysis without matching but instead
with covariate adjustment terms for age, weight, gender, and
vascular access: we observed an effect estimate that was
markedly attenuated (1.08; 95% CI 0.98–1.20) and which
was similar to estimates from other cohorts in which weight
was markedly imbalanced across DSL groups and not
matched on.7
A separate (but often conflated) consideration is whether
the association between RxDSL and mortality pertains
equally to all patients or whether there is effect modification.
Marshall et al.5 observed that DSL was potently associated
with mortality among patients with high and intermediate
but not low BMI. Miller et al.7 showed a DSL–mortality
association among women but not among men, presumably
related to issues of body size and composition. Similarly,
Depner’s16 post-hoc analysis of the HEMO Study
demonstrated that more intensive dialysis (although
defined in terms of eKt/V, not DSL per se) reduced
mortality among women but not among men. However, in
this analysis, Depner16 did not detect effect modification on
the basis of body size, whether considered as weight, body
surface area, or body mass index. It is unclear whether the
latter observation relates to limited statistical power (further
complicated by strong implied relationships between gender
and body size18) or indicates a true absence of biological
effect modification. In this study, we did not observe effect
modification on the basis of body weight, gender, or age.
Table 1 (Continued)
Total (N¼ 10,571) RxDSLo240 (n¼ 6791) RxDSL X240 (n¼ 3780) P-value
5–6 2524 (23.9%) 1594 (23.5%) 929 (24.6%)
46 3076 (29.1%) 1863 (27.4%) 1213 (32.1%)
Missing 34 (0.3%) 17 (0.3%) 17 (0.5%)
Hemoglobin (g/dl) 12.1±1.4 12.0±1.4 12.2±1.4 o0.001
Abbreviations: DSL, dialysis session length; IQR, interquartile range; RxDSL, prescribed DSL; SBP, systolic blood pressure.
aValues presented as mean (s.d.) or n (%), except where indicated. Across prescribed session length groups, significance was assessed by T-test for continuous variables and
by w2 test for categorical variables.
bNumber of dialysis sessions missed during the 30-day exposure period.
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However, inasmuch as these were secondary analyses
(although stipulated a priori) and contained few patients at
the extremes of body size (because of matching), further
investigation is needed.
Mechanisms underlying the RxDSL–mortality association
may be multifactorial and likely relate in part to fluid
dynamics and enhanced solute clearance not represented by
URR or Kt/V. Shorter DSL implies less time for fluid removal,
ergo higher ultrafiltration rates. In our study, ultrafiltration
rates were lower among RxDSL X240 subjects than among
their matched RxDSL o240 counterparts, despite the fact
that RxDSL 4240 subjects had higher IDWG. Prior studies
indicate that higher ultrafiltration rates are associated with
increased all-cause3,8,9 and cardiovascular mortality,9 possibly
Table 2 | Comparison of age, gender, vascular access type,
and post-dialysis weights between matched RxDSL o240
and RxDSL X240 subjects in the primary analysisa
RxDSL o240
(N¼ 2382)
RxDSL X240
(N¼ 2382) P-value
Matching factors
Age (years) —
Mean±s.d. 61.7±13.0 61.6±13.0
Median (IQR) 62.0 (53.0, 72.0) 62.0 (53.0, 72.0)
(min., max.) (22, 96) (20, 94)
Female 900 (37.8%) 900 (37.8%) —
Access —
Fistula 986 (41.4%) 986 (41.4%)
Graft 665 (27.9%) 665 (27.9%)
Catheter 730 (30.7%) 730 (30.7%)
Missing 1 (0.04%) 1 (0.04%)
Post-dialysis weight
(kg)
—
Mean±s.d. 76.7±14.9 76.7±14.9
Median (IQR) 75.3 (66.1, 85.6) 75.3 (66.0, 85.7)
(min., max.) (41.5, 153.3) (41.6, 153.2)
Other covariates
Interdialytic weight
gain (kg)
2.6±1.0 2.9±1.1 o0.001
Ultrafiltration rate
(ml/h/kg)
10.2±4.2 9.5±3.6 o0.001
Race o0.001
Non-black 1473 (61.8%) 1328 (55.8%)
Black 895 (37.6%) 1032 (43.3%)
Missing 14 (0.6%) 22 (0.9%)
Diabetes 1271 (53.4%) 1399 (58.7%) o0.001
Coronary artery
disease
291 (12.2%) 344 (14.4%) 0.02
Congestive heart
failure
856 (35.9%) 991 (41.6%) o0.001
Vintage (years) 0.08
o1 617 (25.9%) 580 (24.4%)
1–2 380 (16.0%) 341 (14.3%)
2–4 580 (24.4%) 567 (23.8%)
X4 799 (33.5%) 885 (37.2%)
Missing 6 (0.3%) 9 (0.4%)
Pre-dialysis SBP (mm
Hg)
0.53
p130 326 (13.7%) 351(14.7%)
130–150 798 (33.5%) 798 (33.5%)
150–170 822 (34.5%) 822 (34.5%)
4170 436 (18.3%) 436 (18.3%)
Urea reduction ratio
(%)
73.4±4.9 75.2±5.2 o0.001
Missed sessionsb 0.88
0 1677 (70.4%) 1700 (71.4%)
1 231 (9.7%) 229 (9.6%)
2 217 (9.1%) 216 (9.1%)
3 74 (3.1%) 64 (2.7%)
X4 183 (7.7%) 173 (7.3%)
Albumin (g/dl) 0.07
p3 144 (6.1%) 162 (6.8%)
3–3.5 406 (17.0%) 454 (19.1%)
3.5–4 1061 (44.5%) 1071 (45.0%)
44 760 (31.9%) 680 (28.6%)
Missing 11 (0.5%) 15 (0.6%)
Creatinine 0.02
Quartile 1 550 (23.1%) 619 (26.0%)
Quartile 2 576 (24.2%) 564 (23.7%)
Quartile 3 591 (24.8%) 593 (24.9%)
Quartile 4 588 (24.7%) 511 (21.5%)
Missing 77 (3.2%) 95 (4.0%)
Table 2 (Continued)
RxDSL o240
(N¼ 2382)
RxDSL X240
(N¼ 2382) P-value
Phosphorus (mg/dl) 0.38
p4 465 (19.5%) 493 (20.7%)
4–5 635 (26.7%) 583 (24.5%)
5–6 578 (24.3%) 584 (24.5%)
46 698 (29.3%) 712 (29.9%)
Missing 6 (0.3%) 10 (0.4%)
Hemoglobin (g/dl) 12.0±1.4 12.2±1.5 o0.001
Abbreviations: DSL, dialysis session length; IQR, interquartile range; RxDSL, prescribed
DSL; SBP, systolic blood pressure.
aValues presented (%) except where indicated.
bNumber of dialysis sessions missed during the 30-day exposure period.
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1.28 (0.98–1.67) 1.30 (1.02–1.68)
P-trend=0.038P-difference=0.005
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Figure 1 | Adjusted associations between prescribed dialysis
session length (RxDSL) and mortality based on the Cox
regression models. Subjects were matched on gender, access type
(fistula, graft, catheter), age (±2.5 years), and post-dialysis weight
(±1 kg). The multivariable models contained covariate terms for age,
race (Black, non-Black), post-dialysis weight, interdialytic weight gain
(p0, 1–1.49, 1.5–2.99, 3.0–3.99, and X4.0 kg), vintage (o1, 2, 3, X4
years), diabetes, coronary artery disease, congestive heart failure,
missed dialysis sessions over 30 days (0, 1, 2, 3, X4), creatinine
(quartiles), albumin (p3, 3–3.5, 3.5–4,44 g/dl), phosphorus (p4, 4–5,
5–6, X6mg/dl), and pre-dialysis systolic blood pressure (p130,
130–150, 150–170,4170mmHg). Models were stratified on matched
pair assignment. CI, confidence interval; HR, hazard ratio; ref.,
reference.
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on the basis of consequent cardiac stunning and subclinical
ischemia19 and hemodynamic destabilization.20 The role of
enhanced solute clearance with longer membrane contact
should not be discounted. Longer DSL enables greater
removal of urea, creatinine, phosphorus, and b-2-
microglobulin, even under experimental conditions in
which Kt/V is held constant.21–23 The present study was
unable to mechanistically determine whether and to what
degree differences in ultrafiltration rates and solute clearance
may mediate the DSL–mortality association. However, our
results did show mild attenuation of the HR for RxDSL
o240 when URR was included in the model, suggesting that
enhanced solute clearance may represent one causal pathway.
Further study in this regard is needed.
The strengths of this study include its large, nationally
representative cohort, the use of standardized protocols for
data collection across HD units, and the use of tight
matching parameters to create strict control for the most
influential confounders. Several limitations of this study bear
mention. First, observational data carry an inherent risk for
uncontrolled confounding and bias. To minimize the
risk of residual confounding, we matched subjects on
factors identified as the strongest confounders of the
RxDSL–mortality association, resulting in near-perfect
balance in weight, age, gender, and vascular access type. To
minimize confounding from other factors, we adjusted
estimates for additional variables plausibly associated with
both mortality and RxDSL, such as dialytic vintage, relevant
comorbidities, and biochemical indices. Because of data
limitations, we were unable to consider additional nutritional
markers such as CRP and nPCR and were unable to include a
detailed analysis of cardiac status (e.g., left ventricular
ejection fraction). We cannot exclude the possibility of
residual confounding related to these variables or other
unconsidered variables. A second weakness may be in the
consideration of RxDSL as the exposure of interest. RxDSL is
less directly biologically relevant compared with delivered
DSL. The selection of RxDSL, however, allowed us to study
Stratified association between shorter RxDSL and mortality
0.9 1 1.25 1.75
1.20 (0.94–1.53)
1.32 (0.93–1.86)
1.67 (1.12–2.49)
1.34 (0.92–1.96)
1.52 (0.98–2.37)
1.34 (1.06–1.69)
1.26 (1.02–1.56)
Age (years)
Gender
65
n =1415 Matched pairs
>65
n =967 Matched pairs
RxDSL240 ref. for each
Post-dialysis weight (kg)
Quartile 1 (66)
n = 590 Matched pairs
Quartile 2 (67–75)
n = 580 Matched pairs
Quartile 3 (76–86)
n = 629 Matched pairs
Quartile 4 (>86)
n = 583 Matched pairs
Male
n =1482 Matched pairs
Female
n = 900 Matched pairs 1.22 (0.93–1.60)
Figure 2 | Adjusted associations between prescribed dialysis session length (RxDSL) o240 (ref RxDSL X240) and mortality in
restriction subgroup analysis considering age, gender, and post-dialysis weight. RxDSL o240 and RxDSL X240 subjects were pair-
matched on gender, access type (fistula, graft, catheter), age (±2.5 years), and post-dialysis weight (±1 kg). The multivariable models
contained covariate terms for age, race (Black, non-Black), post-dialysis weight, interdialytic weight gain (p0, 1–1.49, 1.5–2.99, 3.0–3.99, and
X4.0 kg), vintage (o1, 2, 3,X4 years), diabetes, coronary artery disease, congestive heart failure, missed dialysis sessions over 30 days (0, 1, 2,
3,X4), creatinine (quartiles), albumin (p3, 2–3.5, 3.5–4,44 g/dl), phosphorus (p4, 4–5, 5–6,X6mg/dl), and predialysis systolic blood pressure
(p130, 130–150, 150–170,4170mmHg). Models were stratified on matched pair assignment. The reference group for all analyses was RxDSL
X240min.
Table 3 | Adjusted associations between RxDSLo240 (vs.
RxDSLX240) and mortality among matched pairs in which
differences in RxDSL were o30, ¼ 30, and 430mina
RxDSLX240 RxDSLo240Time difference
Adjusted HR (95% CI) Adjusted HR (95% CI)a
o30Min
(n¼ 435 matched pairs)
1.00 (reference) 1.12 (0.75–1.66)
¼ 30Min
(n¼ 938 matched pairs)
1.00 (reference) 1.38 (1.03–1.84)
430Min
(n¼ 1009 matched pairs)
1.00 (reference) 1.41 (1.08–1.84)
Abbreviations: CI, confidence interval; HR, hazard ratio; RxDSL, prescribed dialysis
session length.
aRxDSLo240 and RxDSLX240 subjects were matched on gender, access type
(fistula, graft, catheter), age (±2.5 years), and post-dialysis weight (±1 kg).
Multivariable models contained covariate terms for age, race (Black, non-Black),
post-dialysis weight, interdialytic weight gain (p0, 1–1.49, 1.5–2.99, 3.0–3.99, and
X4.0 kg), vintage (o1, 2, 3, X4 years), diabetes, coronary artery disease, congestive
heart failure, missed dialysis sessions over 30 days (0, 1, 2, 3, X4), creatinine
(quartiles), albumin (p3, 3–3.5, 3.5–4, 44g/dl), phosphorus (p4, 4–5, 5–6, X6mg/
dl), and pre-dialysis systolic blood pressure (p130, 130–150, 150–170,
4170mmHg). Models were stratified on matched pair assignment.
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Table 4 | Comparison of age, gender, vascular access type, and post-dialysis weights between matched RxDSLo210,
RxDSL210-239, and RxDSLX240 subjectsa
RxDSLo210 (N¼ 691) RxDSL210–239 (N¼ 691) RxDSLX240 (N¼ 691) P-value
Matching factors
Age (years) —
Mean±s.d. 64.9±11.9 64.8±11.8 64.8±11.8
Median (IQR) 65.0 (57.0, 75.0) 66.0 (57.0, 74.0) 65.0 (56.0, 74.0)
(min., max.) (25.0, 87.0) (22.0, 90.0) (24.0, 88.0)
Female 290 (42.0%) 290 (42.0%) 290 (42.0%) —
Access —
Fistula 271 (39.2%) 271 (39.2%) 271 (39.2%)
Graft 212 (30.7%) 212 (30.7%) 212 (30.7%)
Catheter 208 (30.1%) 208 (30.1%) 208 (30.1%)
Post-dialysis weight (kg) —
Mean±s.d. 71.6±11.0 71.6±11.0 71.6±11.0
Median (IQR) 70.7 (63.7, 78.7) 70.6 (63.6, 78.7) 70.6 (63.6, 78.6)
(min., max.) (45.8, 118.5) (45.8, 117.7) (45.5, 117.8)
Other covariates
Interdialytic weight gain (kg) 2.3±0.9 2.6±1.1 2.7±1.1 o0.001
Ultrafiltration rate (ml/h/kg) 10.7±4.3 10.2±4.0 9.5±3.7 o0.001
Race o0.001
Non-black 486 (70.4%) 421 (60.9%) 381 (55.1%)
Black 204 (29.5%) 265 (38.4%) 305 (44.2%)
Missing 1 (0.1%) 5 (0.7%) 5 (0.7%)
Diabetes 342 (49.5%) 381 (55.1%) 413 (59.8%) 0.001
Coronary artery disease 88 (12.7%) 94 (13.6%) 105 (15.2%) 0.41
Congestive heart failure 231 (33.4%) 253 (36.6%) 273 (39.5%) 0.06
Vintage (years) 0.05
o1 171 (24.7%) 185 (26.8%) 160 (23.1%)
1–2 107 (15.5%) 113 (16.4%) 87 (12.6%)
2–4 186 (26.9%) 148 (21.4%) 174 (25.2%)
X4 225 (32.6%) 245 (35.5%) 268 (38.8%)
Missing 2 (0.3%) 0 (0.0%) 2 (0.3%)
Pre-dialysis SBP (mmHg) 0.97
p130 99 (14.3%) 97 (14.0%) 105 (15.2%)
130–150 222 (32.1%) 219 (31.7%) 226 (32.7%)
150–170 246 (35.6%) 242 (35.0%) 230 (33.3%)
4170 124 (18.0%) 133 (19.3%) 130 (18.8%)
Urea reduction ratio (%) 73.2±4.6 74.4±4.9 76.1±5.0 0.18
Missed sessionsb 0.37
0 486 (70.4%) 511 (74.0%) 514 (74.4%)
1 63 (9.1%) 66 (9.5%) 57 (8.3%)
2 52 (7.5%) 47 (6.8%) 56 (8.1%)
3 25 (3.6%) 17 (2.5%) 21 (3.0%)
X4 65 (9.4%) 50 (7.2%) 43 (6.2%)
Albumin (g/dl) 0.02
p3 36 (5.2%) 45 (6.5%) 57 (8.3%)
3–3.5 116 (16.8%) 131 (19.0%) 134 (19.4%)
3.5–4 302 (43.7%) 316 (45.7%) 327 (47.3%)
44 235 (34.0%) 196 (28.4%) 171 (24.7%)
Missing 2 (0.3%) 3 (0.4%) 2 (0.3%)
Creatinine 0.89
Quartile 1 164 (23.7%) 167 (24.2%) 180 (26.1%)
Quartile 2 174 (25.2%) 162 (23.4%) 172 (24.9%)
Quartile 3 163 (23.6%) 176 (25.5%) 168 (24.3%)
Quartile 4 172 (24.9%) 166 (24.0%) 150 (21.7%)
Missing 18 (2.6%) 20 (2.9%) 21 (3.0%)
Phosphorus (mg/dl) 0.29
p4 150 (21.7%) 150 (21.7%) 163 (23.6%)
4–5 205 (29.7%) 185 (26.8%) 165 (23.9%)
5–6 168 (24.3%) 170 (24.6%) 171 (24.8%)
46 167 (24.2%) 184 (26.6%) 187 (27.1%)
Missing 1 (0.1%) 2 (0.3%) 5 (0.7%)
Hemoglobin (g/dl) 12.0±1.3 12.1±1.5 12.2±1.4 0.006
Abbreviations: DSL, dialysis session length; IQR, interquartile range; max., maximum; min., minimum; RxDSL, prescribed DSL; SBP, systolic blood pressure.
aValues presented as n (%), except where indicated.
bNumber of dialysis sessions missed during the 30-day exposure period.
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treatment intention and to reduce confounding from sessions
that may have been truncated because of hemodynamic
instability or nonadherence (manifest as willful curtailment
of HD sessions), which would bias estimates. Third, we
excluded patients with URR o65% so as to consider the
effects of DSL extension beyond what is required to meet
basic clearance goals. Our results, therefore, should not be
extrapolated to patients who have inadequate clearance
metrics, although independent data suggest that dialysis
should be intensified in this setting.24–26
Fourth, DSL was dictated by treating physicians; hence,
the degree to which DSL differences reflect other practice
pattern differences across providers is unknown, and such
differences could confound study results. Because of data
limitations, we cannot provide insight into why some
patients had longer RxDSL compared with others, despite
similar clearance goals. We attempted to minimize center
effect by excluding patients dialyzed at facilities where there
was not at least one subject in each RxDSL category; however,
residual confounding related to individual physician practices
could remain. In addition, prior studies have demonstrated
that longer RxDSL increases clearance of middle molecules
such as phosphate and b-2-microglobulins even when URR
remains constant.21–23 Our multivariable adjustment for
URR does not adequately control for confounding
introduced by enhanced middle-molecule clearance; thus,
residual confounding from clearance not reflected by URR
may remain. Similarly, lower ultrafiltration rates driven by
longer DSL may lead to more consistent dry weight
attainment with fewer hemodynamic complications, and we
are unable to account for such differences in our analysis.
Prospective trials are needed to adequately address the roles
of these important potential clearance and hemodynamic
confounders. Finally, we limited consideration to patients
undergoing dialysis three-times-weekly in-center, with
treatment times between 2.5 and 4.5 h (because this
represents the treatment paradigm for a vast majority of
US HD patients). By matching, we further (implicitly)
excluded patients for whom DSL was deterministic, most
notably those at the extremes of body weight. Thus, our
results should not be extrapolated to patients undergoing
dialysis on the basis of other paradigms, to those with body
weights outside the range studied, or to HD populations
dissimilar from our cohort. In this context, the reader should
be mindful that this study considered data from a single
LDO, and generalizability to the broader US dialysis
population should be undertaken cautiously.
In conclusion, this study demonstrates that, among
chronic HD patients with adequate urea clearance, shorter
RxDSL is associated with increased all-cause mortality
independent of body size. This association follows a
dose–response pattern: incrementally shorter sessions are
associated with higher hazard. Further prospective studies are
needed to confirm and generalize findings and to explore
therapeutic alternatives that might be more acceptable to
patients compared with DSL extension.
MATERIALS AND METHODS
Study design
This study was deemed exempt by the Partners Health Care
Institutional Review Board. All study data were derived from a
cohort of 14,643 randomly selected prevalent adult patients
receiving three-times-weekly in-center HD at one LDO. Cohort
entry was between 1 January 2005 and 16 January 2009. The patients
were dialyzed at one of 1247 outpatient dialysis facilities located
across a diverse geographic distribution within the United States.
Because our intent was to estimate whether longer RxDSL—beyond
that necessary to achieve current adequacy standards—is associated
with improved survival, we excluded subjects with URR o65%.26
URR was selected over Kt/V to minimize collinearity between the
clearance metric and the exposure of interest. To limit undue
influence of patients receiving very short or very long dialysis (who
likely differ in fundamental ways from the general HD population
and in whom decisions between standard-shorter and standard-
longer DSL are likely moot), we excluded patients with RxDSL
o150 or 4270min. To minimize the center effect derived from
units in which RxDSL was deterministic, we excluded patients
undergoing dialysis at facilities without even one subject in each
RxDSL category.
Data collection
The study data were obtained from the LDO’s comprehensive
electronic medical record and collected in keeping with the LDO’s
standard clinical protocols. Demographic data were recorded by unit
personnel at the time of entry into an LDO unit. Comorbidity
assessment was made by the attending nephrologist upon subject
enrollment into an LDO unit based on interview, examination, and
medical record review and was then updated as dictated by clinical
course. Laboratory parameters were measured at the time of entry
into an LDO unit and thereafter on a biweekly or monthly basis. As
per standard clinical procedure, dialytic session data including the
exposure, RxDSL, were recorded on a session-by-session basis.
Predialysis systolic blood pressure was measured at the start of each
dialysis session, and post-dialysis weight was measured following the
conclusion of each dialytic procedure. Post-dialysis weight was
selected over estimated dry weight as the operational metric of body
size because documentation of the latter often lags behind actual
body weight changes. Missing data for height precluded the use of
body mass index, body surface area, or other anthropometrics. Date
of death and attributed cause of death were recorded in the medical
record by dialysis unit staff.
Time sequence and designation of exposures and outcome
The exposure of interest, RxDSL, was considered as the mean of
(typically 12) values over the 30-day period following cohort entry
(30-day mean RxDSL demonstrated excellent correlation with 60-
day (r¼ 0.98) and 90-day (r¼ 0.96) means; a 30-day exposure
window was thus adopted to minimize potential survivor bias).
RxDSL was selected over delivered session length as the exposure of
interest because the use of RxDSL: (1) better reflects treatment
intention, (2) minimizes bias otherwise incurred because of
differential adherence to RxDSL (i.e., willful curtailment of
treatments), and (3) minimizes confounding on the basis of health
events that trigger premature cessation of dialysis and independently
predispose to death.
Covariate data on demographic characteristics (age, gender, race,
vascular access type, and dialytic vintage) and comorbidities
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(diabetes, coronary artery disease, congestive heart failure) were
considered as of cohort entry. Biochemical covariates (URR,
albumin, creatinine, and phosphate) were considered as the latest
values measured during the 30-day exposure window. Dialysis
session data (post-dialysis weight, interdialytic weight gain, and
predialysis systolic blood pressure) were considered as per RxDSL.
The outcome of interest was death from any cause. Cause-
specific mortality was not considered given that the attributed cause
of death data have not been validated and were in some instances
missing. Subjects were considered at risk for outcome starting on
day 31 following cohort entry and remained at risk until they died
or were censored for transfer of care, change in dialysis modality,
renal transplant, or end of study (21 February 2009). Subjects failing
to maintain LDO enrollment during the 30-day exposure period
were excluded from analysis. On the basis of varying cohort entry
times, subjects were eligible to contribute up to 48.7 months of
potential at-risk time.
Statistical analyses
In the primary analysis, RxDSL was considered as a dichotomous
variable (o240 andX240min) based on a clinically relevant cutoff
point. In the secondary analysis, RxDSL was considered as a three-
level categorical variable (o210, 210–239, and X240min). Baseline
subject characteristics were described as counts and proportions for
categorical variables and as means and standard deviations for
continuous variables. Bivariable comparisons across RxDSL cate-
gories were made using contingency table methods and w2 testing,
Student’s t-tests, or analysis of variance.
To maximally control for the most compelling confounders,
subjects were matched on the basis of age (±2.5 years), gender
(identical), vascular access type (identical), and post-dialysis weight
(nearest neighbor with caliper width not exceeding ±1 kg). In the
primary analysis, RxDSL o240 and RxDSL X240 subjects were
matched 1:1; in the secondary analysis RxDSL o210,
RxDSL210–239, and RxDSL X240 subjects were matched 1:1:1.
All survival analyses were then stratified on matched pair/triplet
assignment. Adjusted associations were estimated using multi-
variable Cox proportional hazard models with the inclusion of
covariate terms for other variables thought to be plausibly associated
with both RxDSL and survival and that exhibited significant
unadjusted associations with RxDSL and survival. Multivariable
models were adjusted for age, race (Black, non-Black), post-dialysis
weight (kg), vintage (o1, 2, 3, X4 years), diabetes, coronary artery
disease, congestive heart failure, missed dialysis sessions over 30 days
(0, 1, 2, 3, X4), creatinine (quartiles mg/dl), albumin (p3, 3–3.5,
3.5–4, 44 g/dl), phosphorus (p4, 4–5, 5–6, X6mg/dl), and
predialysis systolic blood pressure (p130, 130–150, 150–170,
4170mmHg). Predialysis systolic blood pressure, missed dialysis
sessions, and vintage were not significantly associated with RxDSL
on univariate analyses but were included because of their strong
associations with mortality and for congruity with the published
literature. Ultrafiltration rate and URR were not included because
they were thought to represent plausible causal pathway inter-
mediates (i.e., means by which RxDSL may affect survival). In
addition, covariate terms for age and post-dialysis weight were
included in the multivariable model to adjust for imbalance that
may have persisted despite matching. The specification of
continuous covariates (linear vs. categorical) was guided by each
covariate’s observed association with outcome as assessed by
regression coefficient graphical evaluation, Akaike’s Information
Criterion, and Martingale residual plots. The proportionality
assumption for each model was tested graphically and by Schoenfeld
residual testing (no variables were in violation). The adjusted R2 for
the final model was 0.81.
Effect modification of the DSL–survival association on the basis
of age, gender, and post-dialysis weight was explored through
restriction subgroup analysis; for these analyses, age and post-
dialysis weight were dichotomized at their medians. Significance of
interaction was assessed by likelihood ratio testing of nested models
that did and did not include two-way cross-product terms (factor-
by-exposure). All analyses were performed using STATA 10.0MP
(College Station, TX).
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